SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (1886)4/1/2003 12:14:57 PM
From: scaram(o)uche  Respond to of 2243
 
I provided the OX40L-specific MAb preps for the preclinical rat work that initially attracted Cantab (subsequently merged with Xenova) to the project. Years ago. Interesting project, moving slowly given the efficacy of anti-TNF and funding issues.

I'm not nuts about topoisomerase inhibitors.

Any indications of outright strength in any one project? Thanks for the post.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News